Issues in amiodarone-induced thyrotoxicosis: Update and review of the literature
| Autor: | Igor Tauveron, Thomas Benichou, F. Desbiez, Salwan Maqdasy, Sarah Dallel, Marie Batisse-Lignier, Nathanaëlle Montanier, B. Roche |
|---|---|
| Přispěvatelé: | Service d’Endocrinologie Diabète et Maladies Métaboliques [CHU Clermont-Ferrand], Pôle RHEUNNIRS [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Génétique, Reproduction et Développement (GReD ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Pediatrics
medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment [SDV]Life Sciences [q-bio] Amiodarone 030209 endocrinology & metabolism Diagnostic dilemma Thyroiditis Amiodarone-induced thyrotoxicosis 03 medical and health sciences 0302 clinical medicine Endocrinology Recurrence Risk Factors Tachycardia medicine Humans In patient business.industry Thyroid Thyroidectomy General Medicine medicine.disease 3. Good health Thioamides medicine.anatomical_structure Thyrotoxicosis 030220 oncology & carcinogenesis Etiology business Anti-Arrhythmia Agents medicine.drug |
| Zdroj: | Annales d'Endocrinologie Annales d'Endocrinologie, Elsevier Masson, 2019, 80, pp.54-60. ⟨10.1016/j.ando.2018.05.001⟩ Annales d'Endocrinologie, 2019, 80, pp.54-60. ⟨10.1016/j.ando.2018.05.001⟩ |
| ISSN: | 0003-4266 2213-3941 |
| DOI: | 10.1016/j.ando.2018.05.001⟩ |
| Popis: | Amiodarone, a benzofuranic iodine-rich pan-anti-arrhythmic drug, induces amiodarone-induced thyrotoxicosis (AIT) in 7-15% of patients. AIT is a major issue due to its typical severity and resistance to anti-thyroid measures, and to its negative impact on cardiac status. Classically, AIT is either an iodine-induced thyrotoxicosis in patients with abnormal thyroid (type 1), or due to acute thyroiditis in a "healthy" thyroid (type 2). Determination of the type of AIT is a diagnostic dilemma, as characteristics of both types may be present in some patients. As it is the main etiological factor in AIT, it is recommended that amiodarone treatment should be stopped; however, it may be the only anti-arrhythmic option, needing to be either continued or re-introduced to improve cardiovascular survival. Recently, a few studies demonstrated that amiodarone could be continued or re-introduced in patients with history of type-2 AIT. However, in the other patients, it is recommended that amiodarone treatment be interrupted, to improve response to thioamides and to alleviate the risk of AIT recurrence. In such patients, thyroidectomy is recommended once AIT is under control, allowing safe re-introduction of amiodarone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect